GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Cash Ratio

Alterity Therapeutics (Alterity Therapeutics) Cash Ratio : 0.00 (As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Alterity Therapeutics's Cash Ratio for the quarter that ended in Sep. 2023 was 0.00.

Alterity Therapeutics has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Alterity Therapeutics's Cash Ratio or its related term are showing as below:

ATHE' s Cash Ratio Range Over the Past 10 Years
Min: 2.6   Med: 8.74   Max: 13.79
Current: 3.6

During the past 13 years, Alterity Therapeutics's highest Cash Ratio was 13.79. The lowest was 2.60. And the median was 8.74.

ATHE's Cash Ratio is ranked better than
55.74% of 1525 companies
in the Biotechnology industry
Industry Median: 2.9 vs ATHE: 3.60

Alterity Therapeutics Cash Ratio Historical Data

The historical data trend for Alterity Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Cash Ratio Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.34 3.39 9.16 5.98 3.60

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.84 - 3.60 - -

Competitive Comparison of Alterity Therapeutics's Cash Ratio

For the Biotechnology subindustry, Alterity Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Cash Ratio falls into.



Alterity Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Alterity Therapeutics's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=10.587/2.941
=3.60

Alterity Therapeutics's Cash Ratio for the quarter that ended in Sep. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alterity Therapeutics  (NAS:ATHE) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Alterity Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (Alterity Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Alterity Therapeutics (Alterity Therapeutics) Headlines

From GuruFocus